The Evolving IPF Landscape
What Nerandomilast Means for Future Antifibrotic Development In recent blogs we have reflected on the promise shown by the orally-delivered preferential PDE4B inhibitor, nerandomilast, now approved by the FDA for the treatment of IPF. After many years of negative clinical data from many programs, and frustration within the field, this molecule now shows promise as […]
Society for Medicines Research (SMR) Meeting on Women’s Health
Darcey Black, Translational Science Director at TherapeutAix, will be attending and co-chairing a session at the forthcoming SMR Meeting on Women’s Health, taking place at Friends House, London, on 17th June. The one-day meeting will bring together a panel of women’s health experts comprising leading researchers from academia, biotech and pharma. They will describe the […]
Biking for Action Medical Research
Our co-founder and Director of Translational, Darcey Black, is planning to take part in the BiotechBikers “Catalyst” Charity Event, a 250-mile cycle ride from London to Bruges, on 8th to 10th May 2025. The event will raise funds for Action Medical Research. Action Medical Research (www.action.org.uk) is the leading UK charity dedicated to funding […]